HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carol Addy Selected Research

Obesity

1/2016Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
8/2012Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
12/2010Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.
10/2010Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
11/2008Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
6/2008Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
4/2008Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
1/2008The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
3/2005Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess.
3/2003Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carol Addy Research Topics

Disease

10Obesity
01/2016 - 03/2003
4Type 2 Diabetes Mellitus (MODY)
01/2017 - 03/2005
3Weight Loss (Weight Reduction)
01/2008 - 10/2006
1Pruritus (Itching)
11/2023
1Nausea
11/2023
1Vomiting
11/2023
1Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
11/2023
1Abdominal Pain (Pain, Abdominal)
11/2023
1Cholestasis
11/2023
1Diarrhea
11/2023
1Non-alcoholic Fatty Liver Disease
01/2023
1Hypertriglyceridemia
08/2017
1Hypoglycemia (Reactive Hypoglycemia)
01/2017
1Body Weight (Weight, Body)
03/2016
1Parkinson Disease (Parkinson's Disease)
07/2009
1Overweight
10/2006
1Endometrial Neoplasms (Endometrial Cancer)
03/2003

Drug/Important Bio-Agent (IBA)

7N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA
08/2012 - 01/2008
4CannabinoidsIBA
08/2012 - 01/2008
32- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA
01/2017 - 01/2016
2Peroxisome Proliferator-Activated Receptors (PPAR)IBA
11/2023 - 01/2023
22- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA
11/2023 - 01/2023
2Hormones (Hormone)IBA
08/2007 - 03/2003
2neuropeptide Y5 receptorIBA
08/2007 - 10/2006
2trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamideIBA
08/2007 - 10/2006
2LeptinIBA
03/2005 - 03/2003
1Ursodeoxycholic Acid (Urso)FDA LinkGeneric
11/2023
1Alkaline PhosphataseIBA
11/2023
1Sterol Regulatory Element Binding Protein 1IBA
08/2017
1TabletsIBA
01/2017
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
03/2016
1Dipeptidyl-Peptidase IV InhibitorsIBA
03/2016
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
07/2009
1N-Methylaspartate (NMDA)IBA
07/2009
14-methylbenzyl 3- fluoro- 4- ((pyrimidin- 2- ylamino)methyl)piperidine- 1- carboxylateIBA
07/2009
1Warfarin (Coumadin)FDA LinkGeneric
11/2008
1sibutramine (Meridia)FDA Link
08/2007
1Orlistat (Xenical)FDA Link
08/2007
1Neuropeptide YIBA
08/2007
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2005
1CytokinesIBA
03/2005
1Interleukin-10 (Interleukin 10)IBA
03/2005
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
03/2005
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
03/2005
1Interleukin-6 (Interleukin 6)IBA
03/2005
1Therapeutic UsesIBA
03/2005
1C-Reactive ProteinIBA
03/2005
1pegylated leptinIBA
03/2005
1recombinant methionyl human leptinIBA
03/2005
1Insulin-Like Growth Factor Binding Protein 3IBA
03/2003
1Insulin-Like Growth Factor II (Somatomedin A)IBA
03/2003
1AdiponectinIBA
03/2003
1Insulin-Like Growth Factor I (IGF-1)IBA
03/2003

Therapy/Procedure

1Therapeutics
01/2008